Skip to main content
SpringerLink
Log in
Book cover

Statin-Associated Muscle Symptoms pp 35–42Cite as

The Patient Perspective on Statin-Associated Muscle Symptoms

  • Chapter
  • First Online:

  • 458 Accesses

Part of the book series: Contemporary Cardiology ((CONCARD))

Abstract

Statin-associated muscle symptoms (SAMS) are relatively rare in controlled clinical trials, at 1% or less in excess vs placebo, yet are reported by 10–30% of statin-taking patients in clinical practice. SAMS are the most common reason for patient-initiated, statin discontinuation, consist of many different symptoms, and have an unpredictable timing of onset. Also, although tolerated by many patients, SAMS can be severe and even debilitating. On the positive side, SAMS are predicted by several physiologic and attitudinal factors, seem less likely with certain statins (especially fluvastatin), may respond favorably to clear provider-patient communication, and often can be resolved simply by statin rechallenge. Greater provider understanding of the patient’s perspectives of SAMS may facilitate achievement of long-term statin persistence and effective cardiovascular disease prevention.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   79.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   99.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002;288(4):462–7.

    Article  Google Scholar 

  2. Benner JS, Glynn RJ, Mogun H, Neumann PJ, Weinstein MC, Avorn J. Long-term persistence in use of statin therapy in elderly patients. JAMA. 2002;288(4):455–61.

    Article  Google Scholar 

  3. Cohen JD, Brinton EA, Ito MK, Jacobson TA. Understanding Statin Use in America and Gaps in Patient Education (USAGE): an internet-based survey of 10,138 current and former statin users. J Clin Lipidol. 2012;6(3):208–15.

    Article  Google Scholar 

  4. Newman CB, Preiss D, Tobert JA, Jacobson TA, Page RL 2nd, Goldstein LB, et al. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol. 2019;39(2):e38–81.

    Article  CAS  Google Scholar 

  5. Franc S, Dejager S, Bruckert E, Chauvenet M, Giral P, Turpin G. A comprehensive description of muscle symptoms associated with lipid-lowering drugs. Cardiovasc Drugs Ther. 2003;17(5–6):459–65.

    Article  CAS  Google Scholar 

  6. Buettner C, Davis RB, Leveille SG, Mittleman MA, Mukamal KJ. Prevalence of musculoskeletal pain and statin use. J Gen Intern Med. 2008;23(8):1182–6.

    Article  Google Scholar 

  7. Bruckert E, Hayem G, Dejager S, Yau C, Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients--the PRIMO study. Cardiovasc Drugs Ther. 2005;19(6):403–14.

    Article  CAS  Google Scholar 

  8. Zhang H, Plutzky J, Skentzos S, Morrison F, Mar P, Shubina M, et al. Discontinuation of statins in routine care settings: a cohort study. Ann Intern Med. 2013;158(7):526–34.

    Article  Google Scholar 

  9. Nissen SE, Dent-Acosta RE, Rosenson RS, Stroes E, Sattar N, Preiss D, et al. Comparison of PCSK9 inhibitor evolocumab vs ezetimibe in statin-intolerant patients: design of the goal achievement after utilizing an anti-PCSK9 antibody in statin-intolerant subjects 3 (GAUSS-3) trial. Clin Cardiol. 2016;39(3):137–44.

    Article  Google Scholar 

  10. Moriarty PM, Thompson PD, Cannon CP, Guyton JR, Bergeron J, Zieve FJ, et al. Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: the ODYSSEY ALTERNATIVE randomized trial. J Clin Lipidol. 2015;9(6):758–69.

    Article  Google Scholar 

  11. Wei MY, Ito MK, Cohen JD, Brinton EA, Jacobson TA. Predictors of statin adherence, switching, and discontinuation in the USAGE survey: understanding the use of statins in America and gaps in patient education. J Clin Lipidol. 2013;7(5):472–83.

    Article  Google Scholar 

  12. Jacobson TA, Khan A, Maki KC, Brinton EA, Cohen JD. Provider recommendations for patient-reported muscle symptoms on statin therapy: insights from the Understanding Statin Use in America and Gaps in Patient Education survey. J Clin Lipidol. 2018;12(1):78–88.

    Article  Google Scholar 

  13. Jacobson TA, Cheeley MK, Jones PH, La Forge R, Maki KC, Lopez JAG, et al. The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy. J Clin Lipidol. 2019;13(3):415–24.

    Article  Google Scholar 

  14. Nichols GA, Koro CE. Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007;29(8):1761–70.

    Article  CAS  Google Scholar 

  15. Karalis DG, Wild RA, Maki KC, Gaskins R, Jacobson TA, Sponseller CA, et al. Gender differences in side effects and attitudes regarding statin use in the Understanding Statin Use in America and Gaps in Patient Education (USAGE) study. J Clin Lipidol. 2016;10(4):833–41.

    Article  Google Scholar 

  16. Ito MK, Maki KC, Brinton EA, Cohen JD, Jacobson TA. Muscle symptoms in statin users, associations with cytochrome P450, and membrane transporter inhibitor use: a subanalysis of the USAGE study. J Clin Lipidol. 2014;8(1):69–76.

    Article  Google Scholar 

  17. Brinton EA, Maki KC, Jacobson TA, Sponseller CA, Cohen JD. Metabolic syndrome is associated with muscle symptoms among statin users. J Clin Lipidol. 2016;10(4):1022–9.

    Article  Google Scholar 

  18. Brinton EA. Understanding Patient Adherence and Concerns with STatins and MedicatION Discussions with Physicians (ACTION): a survey on the patient perspective of dialogue with healthcare providers regarding statin therapy. Clin Cardiol. 2018;41(6):710–20.

    Article  Google Scholar 

  19. Navar AM, Peterson ED, Li S, Robinson JG, Roger VL, Goldberg AC, et al. Prevalence and management of symptoms associated with statin therapy in community practice: insights from the PALM (Patient and Provider Assessment of Lipid Management) registry. Circ Cardiovasc Qual Outcomes. 2018;11(3):e004249.

    Article  Google Scholar 

  20. Bradley CK, Wang TY, Li S, Robinson JG, Roger VL, Goldberg AC, et al. Patient-reported reasons for declining or discontinuing statin therapy: insights from the PALM registry. J Am Heart Assoc. 2019;8(7):e011765.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Utah Lipid Center, Salt Lake City, UT, USA

    Eliot A. Brinton

Authors
  1. Eliot A. Brinton
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eliot A. Brinton .

Editor information

Editors and Affiliations

  1. Hartford Hospital, University of Connecticut, Hartford, CT, USA

    Paul D. Thompson

  2. Hartford Hospital, University of Connecticut, Hartford, CT, USA

    Beth A. Taylor

Rights and permissions

Reprints and permissions

Copyright information

© 2020 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Brinton, E.A. (2020). The Patient Perspective on Statin-Associated Muscle Symptoms. In: Thompson, P., Taylor, B. (eds) Statin-Associated Muscle Symptoms. Contemporary Cardiology. Springer, Cham. https://doi.org/10.1007/978-3-030-33304-1_5

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-33304-1_5

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-33303-4

  • Online ISBN: 978-3-030-33304-1

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation